Replies to post #170180 on Biotech Values

[DewDiligence]

Provenge was one such case, although it happened in 2007/2009 and might not satisfy your definition of recent.

[jellybean]

TDM-1 in the Theresa trial did not meet the OS at the interim analysis

Votrien in Ovarian cancel did not meet the OS at the interim analysis

Zytiga in the prechemo CRPC population did not meet the OS benefit at the interim look but has in the final analysis